First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
NCT07815678
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671. It will also evaluate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose. Parts 1 and 2 will enroll healthy participants, and Part 3 will enroll otherwise healthy participants with obesity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 25 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
- Last updated on ClinicalTrials.gov
- September 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Research Site · Lake Forest, CA
Minnesota · 1
- Research Site · Dilworth, MN
Texas · 1
- Research Site · Webster, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.